Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CRISPR Therapeutics AG CRSP

Healthcare Biotechnology
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this... see more

Recent & Breaking News (NDAQ:CRSP)

Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY(TM) (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease

Business Wire December 8, 2023

CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease

GlobeNewswire December 4, 2023

 Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY(TM) (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Business Wire November 16, 2023

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

GlobeNewswire November 6, 2023

CRISPR Therapeutics Announces Preclinical Data at the American Heart Association (AHA) Scientific Sessions 2023

GlobeNewswire November 6, 2023

CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease

GlobeNewswire October 31, 2023

CRISPR Therapeutics Trading Halted Today; FDA Advisory Committee to Review Biologics License Application (BLA) for Exagamglogene Autotemcel (exa-cel) in Sickle Cell Disease (SCD)

GlobeNewswire October 31, 2023

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

GlobeNewswire October 16, 2023

CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

GlobeNewswire September 27, 2023

CRISPR Therapeutics Announces Leadership Transition

GlobeNewswire September 7, 2023

CRISPR Therapeutics to Participate in Citi's 18th Annual Biopharma Conference

GlobeNewswire August 30, 2023

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results

GlobeNewswire August 7, 2023

CRISPR Therapeutics to Participate in Goldman Sachs 44th Annual Global Healthcare Conference

GlobeNewswire June 13, 2023

Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress

Business Wire June 9, 2023

FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Business Wire June 8, 2023

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

GlobeNewswire May 8, 2023

CRISPR Therapeutics to Participate Upcoming Investor Conferences

GlobeNewswire May 2, 2023

CRISPR Therapeutics to Participate in Needham's 22nd Annual Healthcare Conference

GlobeNewswire April 13, 2023

Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Business Wire April 3, 2023

CRISPR Therapeutics Announces Departure of Board Member

GlobeNewswire March 29, 2023